SCHEMBL1344382

SCHEMBL1344382

CCCc1ccc(-c2nnn(CC(C)(C)C(=O)NCc3ccccc3Cl)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.46
RAB9A P51151 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
ATM Q13315 1/20 0.45
POLB P06746 1/20 0.44
THRB P10828 1/20 0.44
TP53 P04637 2/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPC1 O15118 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
DDX3X O00571 1/20 0.41
USP2 O75604 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1345924 0.93 THRB (0.39) MAPTRAB9ASMN1; SMN2L3MBTL1ATM
SCHEMBL1345783 0.93 THRB (0.44) MAPTRAB9ASMN1; SMN2L3MBTL1ATM
SCHEMBL1346103 0.92 MAPT (0.49) MAPTRAB9ASMN1; SMN2L3MBTL1ATM
SCHEMBL1345985 0.90 MAPT (0.47) MAPTRAB9ASMN1; SMN2L3MBTL1ATM
SCHEMBL1345983 0.90 LMNA (0.50) MAPTRAB9ASMN1; SMN2L3MBTL1POLB
SCHEMBL1344134 0.89 MAPT (0.49) MAPTRAB9ASMN1; SMN2L3MBTL1ATM
SCHEMBL1346801 0.89 LMNA (0.44) MAPTTP53LMNA
SCHEMBL1346178 0.89 RIPK1 (0.52) MAPTRAB9ASMN1; SMN2ATMTHRB
SCHEMBL1347619 0.88 MAPT (0.48) MAPTRAB9ASMN1; SMN2L3MBTL1ATM
SCHEMBL1346948 0.87 MAPT (0.48) MAPTRAB9ASMN1; SMN2L3MBTL1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063082-B2 E.g., N-[(2-chlorophenyl)methyl]({[5-(4-ethylphenyl)(1,2,3,4-tetraazol-2-yl)]methyl}cyclopropyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction CYTOKINETICS, INC. (US) 2011-11-22 US claimed
US-20080132548-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2008-06-05 US claimed
US-8063082-B2 E.g., N-[(2-chlorophenyl)methyl]({[5-(4-ethylphenyl)(1,2,3,4-tetraazol-2-yl)]methyl}cyclopropyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction CYTOKINETICS, INC. (US) 2011-11-22 US disclosed
US-20080132548-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2008-06-05 US disclosed
WO-2008016676-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132548-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 MAPT 530/4885RAB9A 2065/4885SMN1; SMN2 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.